Post–liver transplantation diabetes mellitus: An association with hepatitis C

Ahmad A. AlDosary, Alnoor S. Ramji, Thomas G. Elliott, Sandra M. Sirrs, David M. Thompson, Siegfried R. Erb, Urs P. Steinbrecher, Eric M. Yoshida – 30 December 2003 – A retrospective study was performed on all liver transplant recipients from British Columbia from 1989 to March 2000 to determine the prevalence and predictive factors of diabetes mellitus (DM) post‐liver transplantation. DM was defined as hyperglycemia requiring treatment with insulin or oral hypoglycemic agents.

Predicting the probability of progression‐free survival in patients with small hepatocellular carcinoma

Steve J. Cheng, Richard B. Freeman, John B. Wong – 30 December 2003 – Allocation of cadaveric livers to patients based on such objective medical urgency data as the Model for End‐Stage Liver Disease (MELD) score may not benefit patients with small hepatocellular carcinomas (HCCs). To ensure that these patients have a fair opportunity of receiving a cadaveric organ, the risk for death caused by HCC and tumor progression beyond 5 cm should be considered.

Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation

Sanjiv Saigal, Suzanne Norris, Paolo Muiesan, Mohamed Rela, Nigel Heaton, John O'Grady – 30 December 2003 – Organ transplant recipients are considered to be at greater risk for developing malignancy because of the prolonged immunosuppression associated with organ grafting. The purpose of this study is to determine risk factors, clinical characteristics, and outcomes of de novo nonlymphoid malignancies after liver transplantation from a large single‐center series.

Safe use of livers from donors with positive hepatitis B core antibody

Cosme Manzarbeitia, David J. Reich, Jorge A. Ortiz, Kenneth D. Rothstein, Victor R. Araya, Santiago J. Munoz – 30 December 2003 – Thirty‐five patients received liver transplants using liver donors who had positive test results for the hepatitis B core antibody (HBcAb). In the same time frame, 195 patients received HBcAb‐negative liver donors. Mean follow up for patients receiving HBcAb‐positive donors was 25 months. All patients receiving HBcAb‐positive donors were monitored for recurrence of hepatitis B (HBV) with HBV DNA assays.

Living donor liver transplantation for giant hepatic hemangioma with Kasabach‐Merritt syndrome with a posterior segment graft

Yuji Kumashiro, Mureo Kasahara, Kazuhiro Nomoto, Masaru Kawai, Katsuya Sasaki, Tetsuya Kiuchi, Koichi Tanaka – 30 December 2003 – We present a case of a giant hepatic hemangioma with Kasabach‐Merritt syndrome, which was cured by living donor liver transplantation. A 48‐year‐old woman complained of abdominal fullness and appetite loss. The laboratory data showed disseminated intravascular coagulation and a morphologic evaluation revealed a giant hepatic hemangioma involving both lobes of the liver.

Venous hemodynamics in living donor right lobe liver transplantation

Gabriel E. Gondolesi, Sander Florman, Cal Matsumoto, Ruoqing Huang, Thomas M. Fishbein, Patricia A. Sheiner, Myron E. Schwartz, Sukru Emre, Swan Thung, Robert Shapiro, Charles M. Miller – 30 December 2003 – We evaluated the influence of portal and hepatic venous hemodynamics on the immediate and 3‐month postoperative function of living donor right lobe grafts. Portal velocity was measured prospectively by ultrasound in 14 consecutive donor/recipient pairs. Velocity was converted to flow with the Moriyasu formula.

Long‐term follow‐up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type)

Ole B. Suhr, Bo‐Göran Ericzon, Styrbjörn Friman – 30 December 2003 – Portuguese type familial amyloid polyneuropathy is a dominantly inherited neuropathic amyloidosis caused by a mutant transthyretin (TTR). Because TTR is produced mainly by the liver, liver transplantation (LT) abolishes production of the amyloidogenic variant TTR. To date, the procedure appears to halt the progress of the disease. However, long‐term outcome is unknown. The aim of the present study is to evaluate the survival of our initial group of unselected liver transplant recipients with FAP.

Subscribe to